Xenbase is experiencing difficulties due to technical problems with the University of Calgary IT infrastructure and may go temporarily offline.

Click on this message to dismiss it.
Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Pflugers Arch. April 1, 2000; 439 (6): 714-22.

Cloning, localisation and functional expression of the human orthologue of the TREK-1 potassium channel.

Meadows HJ , Benham CD , Cairns W , Gloger I , Jennings C , Medhurst AD , Murdock P , Chapman CG .

We have cloned human TREK-1, one of the newly emerging mammalian family of 2-P domain potassium channels. The channel has 411 amino acids with a 41-amino-acid extension at the C-terminus when compared with the cloned mouse TREK-1 channel. Expression of hTREK-1 produced a substantial hyperpolarising shift in resting membrane potential accompanied by the induction of large, outwardly rectifying, non-inactivating currents which were potassium selective. Pharmacologically, hTREK-1-mediated currents were only blocked to a limited extent by classic potassium channel blockers or open channel pore blockers known to potently inhibit other channels. The channel was reversibly potentiated by arachidonic acid. CNS distribution of hTREK-1 is widespread with higher levels being observed in caudate, putamen, amygdala, thalamus and spinal cord. Only low levels of expression were seen in the majority of peripheral regions. Thus, hTREK-1, although functionally and pharmacologically similar to mouse TREK-1, appears to have a more CNS-specific distribution.

PubMed ID: 10784345
Article link: Pflugers Arch.

Genes referenced: kcnk2

My Xenbase: [ Log-in / Register ]
version: [3.11.2]

Major funding for Xenbase is provided by the National Institute of Child Health and Human Development, grant P41 HD064556